Regulation of the human TRAIL gene

TRAIL is a member of the TNF superfamily that induces tumor-selective cell death by engaging the pro-apoptotic death receptors DR4 and DR5. The antitumor potential of the TRAIL pathway has been targeted by several therapeutic approaches including recombinant TRAIL and TRAIL-receptor agonist antibodies among others. Interest in sensitizing tumor cells to TRAIL-mediated apoptosis has driven investigations of TRAIL-receptor gene regulation, though regulation of the TRAIL gene has been less studied. Physiologically, TRAIL serves as a pro-apoptotic effector molecule in the immune surveillance of cancer that is conditionally expressed by immune cells upon stimulation via an interferon-response element that was identified in early studies of the TRAIL gene promoter. Here, we map the TRAIL gene promoter and review studies of TRAIL gene regulation that involve several modalities of gene regulation including transcription factors, epigenetics, single-nucleotide polymorphisms and functionally distinct isoforms.

[1]  M. Vitale,et al.  TRAIL up‐regulation must be accompanied by a reciprocal PKCε down‐regulation during differentiation of colonic epithelial cell: Implications for colorectal cancer cell differentiation , 2012, Journal of cellular physiology.

[2]  Q. Wei,et al.  The calcineurin B subunit induces TNF-related apoptosis-inducing ligand (TRAIL) expression via CD11b-NF-κB pathway in RAW264.7 macrophages. , 2012, Biochemical and biophysical research communications.

[3]  P. Yu,et al.  Novel transcript variants of TRAIL show different activities in activation of NF-κB and apoptosis. , 2011, Life sciences.

[4]  R. Balderas,et al.  Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. , 2011, The Journal of clinical investigation.

[5]  Shing-Jyh Chang,et al.  Pigment Epithelium-derived Factor (PEDF) Promotes Tumor Cell Death by Inducing Macrophage Membrane Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)* , 2011, The Journal of Biological Chemistry.

[6]  W. Hahn,et al.  Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine , 2011, Molecular Cancer Therapeutics.

[7]  H. Weiss,et al.  NFATc1 Regulation of TRAIL Expression in Human Intestinal Cells , 2011, PloS one.

[8]  M. Orloff,et al.  Synergy between TLR3 and IL-18 promotes IFN-γ dependent TRAIL expression in human liver NK cells. , 2011, Cellular immunology.

[9]  S. Husain,et al.  Functional implication of TRAIL −716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor , 2011, Breast Cancer Research and Treatment.

[10]  L. Chau,et al.  Heme Oxygenase-1/Carbon Monoxide Induces Vascular Endothelial Growth Factor Expression via p38 Kinase-dependent Activation of Sp1* , 2010, The Journal of Biological Chemistry.

[11]  G. Savich,et al.  Smac/DIABLO release from the mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation , 2010 .

[12]  M. Bennett,et al.  TRAIL Promotes VSMC Proliferation and Neointima Formation in a FGF-2–, Sp1 Phosphorylation–, and NF&kgr;B-Dependent Manner , 2010, Circulation research.

[13]  Christoph Borner,et al.  XIAP discriminates between type I and type II FAS-induced apoptosis , 2009, Nature.

[14]  Lifen Gao,et al.  sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease , 2009, Immunogenetics.

[15]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[16]  Gabriel Krigsfeld,et al.  TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death , 2008, Cancer biology & therapy.

[17]  D. Lauffenburger,et al.  Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. , 2008, Molecular cell.

[18]  A. Johnson,et al.  Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells. , 2008, Gynecologic oncology.

[19]  T. Griffith,et al.  TNF‐related apoptosis‐inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules , 2008, Journal of leukocyte biology.

[20]  A. Klein-Szanto,et al.  TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. , 2008, The Journal of clinical investigation.

[21]  Mohammed Mohiuddin,et al.  Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. , 2007, Cancer research.

[22]  F. Corallini,et al.  Insulin down‐regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro , 2007, Journal of cellular physiology.

[23]  T. Griffith,et al.  Identification of the Mycobacterial Subcomponents Involved in the Release of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand from Human Neutrophils , 2006, Infection and Immunity.

[24]  J. Hiscott,et al.  Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. , 2006, Biochemical pharmacology.

[25]  A. Ashkenazi,et al.  Delineation of the cell-extrinsic apoptosis pathway in the zebrafish , 2006, Cell Death and Differentiation.

[26]  L. Hofbauer,et al.  Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. , 2006, Atherosclerosis.

[27]  A. Mantovani,et al.  Interferon‐activated neutrophils store a TNF‐related apoptosis‐inducing ligand (TRAIL/Apo‐2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators , 2006, Journal of leukocyte biology.

[28]  T. Griffith,et al.  Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. , 2005, Blood.

[29]  B. Evers,et al.  Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. , 2005, Experimental cell research.

[30]  S. Kikuchi,et al.  TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis , 2005, Journal of Neuroimmunology.

[31]  G. Keren,et al.  The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. , 2005, Journal of the American College of Cardiology.

[32]  S. Lowe,et al.  DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis , 2005, Molecular and Cellular Biology.

[33]  A. Almasan,et al.  Resistance to Apo2 Ligand (Apo2L)/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Apoptosis and Constitutive Expression of Apo2L/TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines , 2005, Journal of Virology.

[34]  E. D. de Vries,et al.  Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus , 2004, Annals of the rheumatic diseases.

[35]  T. Griffith,et al.  Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation1 , 2004, The Journal of Immunology.

[36]  A. Kraft,et al.  Oncogenic Ras Sensitizes Normal Human Cells to Tumor Necrosis Factor-α-Related Apoptosis-Inducing Ligand-Induced Apoptosis , 2004, Cancer Research.

[37]  Yi Luo,et al.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand , 2004, Cancer Research.

[38]  Giovanni Martinelli,et al.  IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. , 2004, Blood.

[39]  T. Wienker,et al.  Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis , 2004, Journal of Neuroimmunology.

[40]  A. Suminoe,et al.  Neutrophil-Derived TNF-Related Apoptosis-Inducing Ligand (TRAIL) , 2004, Cancer Research.

[41]  T. Sakai,et al.  p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y , 2003, Oncogene.

[42]  D. Fraker,et al.  Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. , 2003, Cancer research.

[43]  H. Hollema,et al.  Expression of TRAIL (TNF‐related apoptosis‐inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas , 2003, The Journal of pathology.

[44]  J. Lünemann,et al.  TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis , 2003, The Lancet.

[45]  L. Frati,et al.  The Cyclopentenone-Type Prostaglandin 15-Deoxy-Δ12,14-Prostaglandin J2 Inhibits CD95 Ligand Gene Expression in T Lymphocytes: Interference with Promoter Activation Via Peroxisome Proliferator-Activated Receptor-γ-Independent Mechanisms1 , 2003, The Journal of Immunology.

[46]  C. Gerharz,et al.  TRAIL-β and TRAIL-γ: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential , 2003, British Journal of Cancer.

[47]  YOUHAI H. Chen,et al.  Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice , 2003, Nature Immunology.

[48]  W. El-Deiry,et al.  Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. , 2002, Experimental cell research.

[49]  Rakesh Nagarajan,et al.  FOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand Expression , 2002, The Journal of Biological Chemistry.

[50]  C. Chung,et al.  Potentiation of Fas- and TRAIL-mediated apoptosis by IFN-gamma in A549 lung epithelial cells: enhancement of caspase-8 expression through IFN-response element. , 2002, Cytokine.

[51]  J. Tschopp,et al.  The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex* , 2002, The Journal of Biological Chemistry.

[52]  A. Grosse-Wilde,et al.  Caspase‐10 is recruited to and activated at the native TRAIL and CD95 death‐inducing signalling complexes in a FADD‐dependent manner but can not functionally substitute caspase‐8 , 2002, The EMBO journal.

[53]  M. Butterworth,et al.  Bcl-2 and Bcl-xL Inhibit CD95-mediated Apoptosis by Preventing Mitochondrial Release of Smac/DIABLO and Subsequent Inactivation of X-linked Inhibitor-of-Apoptosis Protein* , 2002, The Journal of Biological Chemistry.

[54]  M. Smyth,et al.  Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1 , 2002, The Journal of Immunology.

[55]  J. Blenis,et al.  Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8* , 2001, The Journal of Biological Chemistry.

[56]  C. Ober,et al.  Three polymorphisms in the 3′ UTR of the TRAIL (TNF-related apoptosis-inducing ligand) gene , 2001, Genes and Immunity.

[57]  H. Chun,et al.  Caspase-10 is an initiator caspase in death receptor signaling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Margot Thome,et al.  Regulation of lymphocyte proliferation and death by flip , 2001, Nature Reviews Immunology.

[59]  Tudor M. Baetu,et al.  Disruption of NF-κB Signaling Reveals a Novel Role for NF-κB in the Regulation of TNF-Related Apoptosis-Inducing Ligand Expression1 , 2001, The Journal of Immunology.

[60]  A. Almasan,et al.  Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. , 2000, Biochemical and biophysical research communications.

[61]  J. Hillert,et al.  Apoptosis mediators FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS , 2000, Neurology.

[62]  B. Evers,et al.  Isolation and molecular characterization of the 5'-upstream region of the human TRAIL gene. , 2000, Biochemical and biophysical research communications.

[63]  J. Tschopp,et al.  Cysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL* , 2000, The Journal of Biological Chemistry.

[64]  Ashkenazi,et al.  Lipopolysaccharide Induces Expression of APO2 Ligand/TRAIL in Human Monocytes and Macrophages , 2000, Scandinavian journal of immunology.

[65]  D. Stuart,et al.  Structure of the TRAIL–DR5 complex reveals mechanisms conferring specificity in apoptotic initiation , 1999, Nature Structural Biology.

[66]  K. Schooley,et al.  Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) , 1999, The Journal of experimental medicine.

[67]  M. Ultsch,et al.  Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. , 1999, Molecular cell.

[68]  B. Oh,et al.  2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. , 1999, Immunity.

[69]  E. Alnemri,et al.  Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. , 1999, Cancer research.

[70]  K. Okumura,et al.  Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of  Type I IFNs , 1999, The Journal of experimental medicine.

[71]  C. Maliszewski,et al.  Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL , 1999, The Journal of experimental medicine.

[72]  E. Alnemri,et al.  Natural Killer (NK) Cell–mediated Cytotoxicity: Differential Use of  TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells , 1998, The Journal of experimental medicine.

[73]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[74]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[75]  John C. Lee,et al.  Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.

[76]  V. Dixit,et al.  TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling , 1998, FEBS letters.

[77]  J. Bell,et al.  Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. , 1998, Journal of immunology.

[78]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[79]  A. Gurney,et al.  A novel receptor for Apo2L/TRAIL contains a truncated death domain , 1997, Current Biology.

[80]  S. Srinivasula,et al.  Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.

[81]  R. Dubose,et al.  Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.

[82]  Henning Walczak,et al.  TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.

[83]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[84]  Arul M. Chinnaiyan,et al.  The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.

[85]  S. Marsters,et al.  Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.

[86]  C A Smith,et al.  Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.

[87]  L. Tartaglia,et al.  A novel domain within the 55 kd TNF receptor signals cell death , 1993, Cell.

[88]  E. E. Gresch.  Genetic Alterations During Colorectal-Tumor Development , 1989 .

[89]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[90]  Marvin B. Shapiro,et al.  RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. , 1987, Nucleic acids research.

[91]  L. Altucci,et al.  Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.

[92]  A. Almasan,et al.  Resistance to Apo 2 Ligand ( Apo 2 L ) / Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand ( TRAIL )-Mediated Apoptosis and Constitutive Expression of Apo 2 L / TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines , 2005 .

[93]  R. Macklis,et al.  TRAIL induction by radiation in lymphoma patients. , 2004, Cancer investigation.

[94]  H. Kwon,et al.  Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. , 2001, Journal of immunology.

[95]  Yusuke Nakamura,et al.  Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association of a T924C polymorphism in the thromboxane A2 receptor gene , 2000, Human Genetics.

[96]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[97]  William E. Grizzle,et al.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis , 1987, Nature.

[98]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.